Profile data is unavailable for this security.
About the company
Brooks Laboratories Limited is an India-based pharmaceutical manufacturing company working on a contract basis. The Company’s segment is Pharmaceutical products, including ingredients and intermediaries. It manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup, and eye/ear drops. Its products under the Carbapenem category are Imipenem 250 (Milligram) mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, and Doripenem 500mg. It offers Penicillins in the form of injections, tablets, and dry syrup. Its general category of products includes liquid injections, dry powder injections and eye/ear drops. Its liquid injections include Iron sucrose 100mg/5ml, Iron sucrose 50mg/2.5ml, Phenytoin sodium 50mg/ml and others. Its dry powder injections include Artesunate 60mg, Artesunate 120mg, Omeprazole 40mg, Rabeprazole 20mg, Pantoprazole 40mg and others.
- Revenue in INR (TTM)888.46m
- Net income in INR216.03m
- Incorporated2002
- Employees323.00
- LocationBrooks Laboratories Ltd502 Andheri, Andheri Kurla RoadMUMBAI 400093IndiaIND
- Phone+91 2 261933100
- Fax+91 2 261933114
- Websitehttps://www.brookslabs.net/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Natural Capsules Ltd | 1.80bn | -119.43m | 1.68bn | 171.00 | -- | 0.7393 | 160.88 | 0.9364 | -11.49 | -11.49 | 178.14 | 219.25 | 0.4361 | 3.90 | 2.85 | 10,514,820.00 | -2.90 | 3.87 | -4.04 | 5.48 | 48.29 | 42.06 | -6.64 | 6.39 | 0.9601 | -0.5847 | 0.3136 | -- | 8.87 | 22.41 | -88.88 | -6.36 | 53.13 | -- |
| Aarey Drugs and Pharmaceuticals Ltd | 3.91bn | 34.35m | 1.90bn | 0.00 | 55.93 | -- | 32.54 | 0.4869 | 1.20 | 1.20 | 136.13 | -- | -- | -- | -- | -- | -- | 1.94 | -- | 4.31 | 1.69 | 3.38 | 0.8787 | 1.20 | -- | -0.8387 | -- | -- | 19.80 | 9.57 | -14.09 | -7.03 | 41.47 | -- |
| Quest Laboratories Ltd | -100.00bn | -100.00bn | 2.11bn | 50.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 25.92 | -- | 34.40 | -- | -- | -- |
| Brooks Laboratories Ltd | 888.46m | 216.03m | 2.17bn | 323.00 | 10.06 | -- | 9.36 | 2.44 | 7.32 | 7.32 | 30.45 | -- | -- | -- | -- | 2,750,638.00 | -- | -14.21 | -- | -23.39 | 38.75 | 25.99 | 24.31 | -25.22 | -- | -- | -- | -- | 3.86 | 3.45 | 49.13 | -- | -18.61 | -- |
| Sat Kartar Life Ltd | -100.00bn | -100.00bn | 2.28bn | 922.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 21.07 | -- | 34.79 | -- | 93.36 | -- | 4.50 | -- | -- | -- | 5.39 | 27.37 | 56.31 | 55.66 | 117.33 | 39.27 | -- |
| Vaidya Sane Ayurved Laboratories Ltd | 979.90m | 87.17m | 2.37bn | 636.00 | 29.11 | 3.49 | 16.97 | 2.42 | 7.73 | 7.73 | 85.76 | 64.41 | 1.27 | 4.62 | 15.21 | -- | 11.32 | 7.04 | 13.25 | 9.52 | 83.84 | 73.31 | 8.91 | 4.29 | 2.32 | 84.89 | 0.0092 | -- | -9.55 | 3.61 | 260.35 | -- | 17.02 | -- |
| Lyka Labs Ltd | 1.34bn | -6.54m | 2.43bn | 499.00 | -- | -- | 32.39 | 1.81 | -0.1801 | -0.1801 | 37.32 | -- | -- | -- | -- | 2,682,217.00 | -- | 2.35 | -- | 3.44 | 60.96 | 61.79 | -0.2546 | 3.29 | -- | -0.3263 | -- | -- | 24.55 | 17.63 | 421.84 | -- | 70.13 | -- |
| Nectar Lifesciences Ltd | 7.17bn | -1.26bn | 2.56bn | 1.79k | -- | -- | -- | 0.3568 | -5.64 | -15.87 | 32.08 | -- | -- | -- | -- | 4,014,993.00 | -- | -1.57 | -- | -2.87 | -7.31 | 15.34 | -17.57 | -2.24 | -- | -3.77 | -- | -- | -0.838 | -6.73 | -2,375.90 | -- | -4.37 | -- |
| Holder | Shares | % Held |
|---|---|---|
| quant Money Managers Ltd.as of 30 Jan 2026 | 2.92m | 9.90% |
